Table 1.
Characteristics of studies included in the systematic review and meta-analysis on lung cancer mortality.
| Authors (year) | Country | Sample size | Death | RR/OR or HR (95%CI) |
|---|---|---|---|---|
| Zhang, B., et al. (8) | Canada | 49,165 | 106 | Smoking: Yes: HR=14.04 (7.56-26.07) Age: Old (>50):HR=1.74(1.45-1.87) |
| Chiyo, M. et al. (7) | Japan | 931 | 293 | Gender: male: HR =1.766 (1.304-2.401) Age: HR=1.015 (1.008-1.027) ILD: Yes: HR=1.903(1.012-3.236) |
| Frostad, A. (23) | Norway | 19,998 | 6710 | Age: Old: aOR=1.04 (1.01-1.06) |
| Kabat, G.C., et al. (25) | China | 1590 | 131 | Duration of HRT use: Yes: aHR=1.51 (1.14–1.99). Contraceptive use: Yes: HR=0.91 (0.78–1.06) |
| Yang, L., et al. (11) | China | 225, 721 | 2145 | Follow up: higher: HR=0.75(0.63-0.93) Residence: Urban: HR=2.28 (2.06-2.52) Sex: Male: HR=1.57 (1.47-1.67) Smoking: Yes: HR=1.77 (1.67-1.87) |
| Roth, K., et al. (10) | Norway | 148 | 40 | Age: >=70=HR= 1.93 (1.14, 3.28) Stage: HR=Stage IB= 1.63 (0.92, 2.89) HR=Stage II-IV=4.16 (1.92, 9.05) |
| Chae, K.J et al. (9) | Korea | 612 | 220 | Age: in yr=HR= 1.03 (1.01–1.05) Smoke: yes=HR= 1.68 (1.22–2.32) History: yes=HR= 1.44 (1.00–2.06) |
| Kuderer, N.M (12). | Canada | 1998 | 472 | Age: a year=HR=1.013 (1.003–1.023) Sex: male=HR=1.183 (0.979–1.430) BMI: <35 kg/m2=HR=0.968 (0.611–1.531) Smoke: Yes=HR=1.551 (1.185–2.030) HPT: Yes=HR=1.131 (0.937–1.365) Anaemia: Yes=HR=1.471 (1.185–1.826) |
| Duran, A.O (13) | Turkey | 330 | 125 | Age: year=1.008 (0.990-1.027) Sex: Male=0.863 (0.479-1.554) BMI: 0.967 (0.924-1.012) Smoking: 1.518 (0.890-2.589) Diabetes: 1.200 (0.655-2.199) HPT: Yes=1.076 (0.627-1.847) Cardiac disease: Yes=1.330 (0.656-2.695) |
| Adair, T (22). | Australia | 2480 | 249 | Tobacco: Yes: OR=1.066 (1.002-1.090) |
| Matakidou, A., et al. (26) | UK | 2561 | 191 | Smoker: Yes: RR= 7.15 (5.70–8.96) Age: 60+: RR=2.02 (1.22–3.34) Relatives: Yes: RR=1.90 (1.30–4.25) |
| Stukenborg, G.J (17). | USA | 14,456 | 519 | Liver disease: Yes=RR=2.60 (1.16-5.87) Pneumonia: Yes=RR= 1.73 (1.24-2.42) Hypertension: Yes=RR=1.83 (1.19-2.81) |
| Licker, M.J., et al. (27) | Switzerland | 1222 | 36 | Respiratory complication: Yes=RR=1.9 (1.9-6.6) |
| Lauritsen, J.M (28). | Danish | 439 | 60 | Smoking=Yes=2.02 (0.80, 6.78) |
| Powell, H.A. et al. (14) | UK | 10991 | 981 | Sex=Male=OR= 1.62(1.17 to 2.25) Age=85+=OR= 2.35(1.12 to 9.01) Stage=IIIA/IA= 2.18 (1.25 to 3.81) |
| Kirkland, R.S (18). | USA | 882 | 67 | interstitial lung disease=Yes=OR=6.14(1.9-19.4) pulmonary HT=Yes=OR=3.1(1.6-6.2) diabetes mellitus=Yes=OR=2.0(1.1-3.3) |
| Thomas, P.A (29). | France | 4498 | 351 | Age: >65=OR=2.1(1.5-2.9) BMI: Underweight: OR=2.2(1.2-4.0) Overweight: OR=0.60(0.4-0.9) |
| Rosen, J.E (30). | USA | 119,146 | 4051 | Age: 5-yr increase=OR=1.5(1.25, 1.77) Sex: Male=OR=1.8 (1.3, 3.28) Race: Non-white=OR=1.10(0.8, 1.56) |
| Gibson, A.J (31). | Canada | 1044 | 233 | Sex: Male=OR=1.48 (1.12–1.95) never-smokers=OR=0.62 (0.41–0.95) Advanced disease at diagnosis=OR=1.85 (1.19–2.88) Receiving systemic anti-cancer therapies (SACT)=OR=0.65 (0.49–0.86) |
| Kozower, B.D (19) | USA | 18,800 | 413 | Age: 10-year increase=OR=1.84 (1.58, 2.15) Sex: Male=OR=1.36 (1.07, 1.73) BMI: 10KG/M2 increase=OR=0.74 (0.58, 0.94) HPT: Yes:=OR=1.10 (0.85, 1.43) Diabetes: Yes:=OR=1.15 (0.82, 1.59) Cardiovascular: Yes=OR=1.09 (0.78, 1.51) Dialysis: Yes=OR=3.97 (1.48,10.64) |
| Jean, R.A (32) | USA/Vreginia | 6435 | 120 | Age: year=OR=1.03(1.013-1.056) Sex: male=OR=1.83 (1.199-2.789) DM: Yes=OR=2.57(1.379-4.808) |
| Romano, P.S (21). | USA/California | 12,439 | 441 | Sex: male=OR=1.5 (1.2,1.8) Age: >79=OR=5.4 (3.5,8.4) Heart: Yes=OR=1.8 (1.5,2.2) Diabetes: Yes=OR=1.5 (1.1,2.2) |
| Kates, M., et al. (15) | USA/NewYork | 1844 | 655 | Sex: male=OR= 1.45 (1.22–1.72) Age: 80-80=OR=2.09 (1.60–2.75) Stage: III vs I=OR=1.27 (1.02–1.59) Heart Failure: Yes=OR=1.54 (1.24–1.93) Cardiovascular: Yes=OR=1.75 (1.39–2.22) Diabetes: Yes=OR=1.70 (1.18–2.45) |
| Breslow, R.A (33). | USA | 20195 | 158 | Smoking: Yes= RR=1.2 (0.8-1.8) |
| Bessö, A., et al. (34) | Sweden | 316 | 92 | Sex: male=RR=1.3(0.76–2.62) Smoking: Yes=3.32 (1.35–8.20) |
| Borsoi, L (35). | Austria | 1000000 | 503/10-6 | Sex: Female=RR= 1.12 (0.81-1.66) Age: RR=0.77(0.29-1.22) |
| Cardenas, V.M (36). | USA | 508,576 | 5,469 | Smoke: Yes=RR= 1.2(0.8-1.8) Sex: Female=RR=1.45 (0.74-2.55) |
| Chow, W.H., et al. (37) | USA | 5263 | 219 | Smoking: Yes=RR=3.5 (1.0-12.6) Beer: Yes=RR=1.8 (1.10-3.30) Meat: Yes=RR=1.3(0.7-2.3) Vitamin C: high=RR=0.8(0.5-1.2) |
| Stoelben, E.,et al. (16) | Germany | 1281 | 131 | Sex: Female=RR=0.56(0.30–1.06) Age: >75=RR=2.46 (1.17–5.16) Stage: I vs II 5.58 1.83–17.07 I vs IIIa 9.01 3.52–23.04 I vs IIIb 17.41 6.62–45.80 I vs IV 21.81 8.29–57.38 |
| Sokolnikov, M.E (38). | Russia | 17,740 | 681 | Sex: Male: RR=7.1 (4.9–10) Age: 75+=RR=4.1 (0.9–10) |
| Kuehnl, A (20). | Germany | 31 | 22 | Sex: male=RR=2.08 0.478–9.025 Age: <65 vs>65=RR=0.98 0.934–1.035 BMI: <25 vs >25= RR=0.95 0.856–1.057 Grade: G1/G2 vs G3/G4=RR=0.32 0.110–0.909 |
| Mansfield, A.S, et al. (24) | USA | 759 | 568 | Surgery= HR, 0.35; 95% CI, 0.18–0.68 Chemotherapy=HR, 2.2; 95% CI, 1.2–4.3 Radiation (ref.) KRS (yes vs no)=HR, 1.7; 95% CI, 1.4–2.2 Age: >76= HR, 1.45: 95% CI, 1.12-2.66 Sex: male=HR, 1.32: 95% CI, 1.06-3.10 |